WO2019060797A1 - Procédé de fabrication de poudres à inhaler - Google Patents

Procédé de fabrication de poudres à inhaler Download PDF

Info

Publication number
WO2019060797A1
WO2019060797A1 PCT/US2018/052329 US2018052329W WO2019060797A1 WO 2019060797 A1 WO2019060797 A1 WO 2019060797A1 US 2018052329 W US2018052329 W US 2018052329W WO 2019060797 A1 WO2019060797 A1 WO 2019060797A1
Authority
WO
WIPO (PCT)
Prior art keywords
powder
total flow
flow energy
tapped density
determining
Prior art date
Application number
PCT/US2018/052329
Other languages
English (en)
Other versions
WO2019060797A9 (fr
Inventor
Mukul C. Dalvi
Seah Kee Tee
Original Assignee
Teva Branded Pharmaceutical Products R&D, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Branded Pharmaceutical Products R&D, Inc. filed Critical Teva Branded Pharmaceutical Products R&D, Inc.
Publication of WO2019060797A1 publication Critical patent/WO2019060797A1/fr
Publication of WO2019060797A9 publication Critical patent/WO2019060797A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
    • G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N19/00—Investigating materials by mechanical methods
    • G01N19/04—Measuring adhesive force between materials, e.g. of sealing tape, of coating

Definitions

  • the embodiments generally relate to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for characterizing the cohesiveness of a powder comprising a drug or active agent to determine its suitability for the manufacture of inhalation powder blends.
  • Inhalation therapy is currently the best option for lung diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Pulmonary delivery allows the use of smaller drug doses and reduced systemic side effects.
  • pulmonary delivery is attractive as a route for systemic administration due to fast absorption by the massive surface area of the alveolar region, the abundant vasculature and thin air-blood barrier, and the avoidance of first pass metabolism. (Ibrahim et al., Medical Devices: Evidence and Research, 201S, 8: 131- 139).
  • DPIs dry powder inhalers
  • pMDIs pressurized metered-dose inhalers
  • Lung deposition improves substantially for particles less than S microns in aerodynamic diameter and decreases substantially for particles with effective aerodynamic diameters of greater than S microns.
  • a drug particle size between 1 and S ⁇ is needed for entry into the deep lung by inhalation and particles of 1-2 ⁇ are most suitable for reaching the small airways, an important target for the treatment of asthma and COPD.
  • DPI drug formulations may be either fine powder drug blended with large carrier particles to prevent aggregation and increase powder flow prior to aerosolization, or may consist of drug alone. In all cases, the powder formulations travel along the airways to deposit in the targeted areas of the lung, and then dissolve to exert their pharmacological effect or are absorbed to reach systemic targets.
  • Powder blends for DPIs typically consist of micronized drug particles blended with an inactive excipient (e.g., lactose, mannitol, trehalose, sucrose, sorbitol, glucose) of larger sizes. These components are usually blended together to form an "interactive mixture" wherein the finer drug particles are strongly adhered to the surface of the carrier particles.
  • Unoptimized powder blends can exhibit interparticulate cohesive forces that cause powder aggregates, making powder dispersion very difficult.
  • Micronized drugs especially drug particles having a diameter within the range of from about 1 ⁇ to about S ⁇ , have a high surface energy and substantial adhesive and cohesive properties.
  • Some APIs used in dry powder inhalation products are particularly challenging to homogenize.
  • the cohesive nature of salmeterol xinafoate is well documented. It is possible to improve homogeneity of salmeterol xinafoate by increasing the blending energy, however, this adversely affects the aerodynamic particle size distribution (i.e., reduces the fine particle dose).
  • AFM cohesive adhesive balance
  • An aspect of the disclosure is to provide a method for characterizing the cohesiveness of a powder comprising a drug or active agent.
  • the method may include (i) optionally conditioning the powder; (ii) determining the tapped density of the powder; (iii) determining the total flow energy of the powder; (iv) calculating an average tapped density and average total flow energy of the powder based on collected data for a plurality of units of the powder; (v) determining whether a correlation exists between the average tapped density and the average total flow energy of the powder; (vi) if a correlation exists, then determining the blend uniformity of the powder; (vii) correlating the blend uniformity with the tapped density and/or total flow energy; and (viii) determining a tapped density threshold and /or total flow energy threshold to achieve satisfactory blend uniformity.
  • powder manufacturers can use the tapped density and /or total flow energy threshold values to select suitable powders.
  • An additional aspect of the disclosure is to provide a method for determining the suitability of powders for manufacturing a powder blend.
  • the method may include: (i) optionally conditioning the powder; (ii) determining the tapped density of the powder; (iii) determining the total flow energy of the powder; (iv) calculating an average tapped density and average total flow energy of the powder based on collected data for a plurality of units of the powder; (v) determining whether a correlation exists between the average tapped density and the average total flow energy of the powder; (vi) if a correlation exists, then determining the blend uniformity of the powder; (vii) correlating the blend uniformity with the tapped density and/or the total flow energy; (viii) determining a tapped density threshold and/or total flow energy threshold to achieve satisfactory blend uniformity; and selecting powders that do not exceed the tapped density threshold and/or total flow energy threshold.
  • tapped density or total flow energy can be used as a surrogate for the cohesiveness of the API bulk batch to predict satisfactory blend uniformity.
  • the embodiments disclosed herein can be used to screen batches of APIs to allow for the selection of batches that will mix under standardized conditions to achieve homogeneous blends.
  • Other objects and features of the embodiments will be in part apparent and in part pointed out hereinafter.
  • FIG. 1 shows a Split Vessel Assembly, in accordance with one or more embodiments.
  • FIG. 2 shows the rotation of the FT4 blade in the conditioning step, in accordance with one or more embodiments.
  • FIG. 3 shows the measurement of work done by downward traverse of the FT4 blade through the previously consolidated power bed, in accordance with one or more embodiments.
  • FIG. 4 shows a graph depicting the correlation between total flow energy and tapped density for salmeterol xinafoate, in accordance with one or more embodiments.
  • FIG. S shows a graph depicting the total flow energy of different salmeterol xinafoate batches, in accordance with one or more embodiments.
  • FIG. 6 shows a graph depicting the tapped density of different salmeterol xinafoate batches, in accordance with one or more embodiments.
  • drug or “active agent” include any agent, drug, composition of matter or mixture which provides a pharmacologic effect that can be
  • active pharmaceutical ingredient means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals.
  • the term includes those components that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect.
  • excipient also “inactive ingredient” as used herein means any component other than an active ingredient.
  • batch means a specific quantity of a product that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during a same cycle of manufacture. Batch refers to the quantity of material and does not specify a mode of manufacture.
  • “Dry powder” refers to a powder composition that typically contains less than about 20% moisture, preferably less than 10% moisture, more preferably contains less than about 5-6% moisture, and most preferably contains less than about 3% moisture, depending upon the particular formulation.
  • a dry powder that is "suitable for pulmonary delivery” refers to a composition comprising solid (i.e., non-liquid) or partially solid particles that are capable of being (i) readily dispersed in/by an inhalation device and (ii) inhaled by a subject so that a portion of the particles reach the lungs to permit penetration into the alveoli .
  • Such a powder is considered to be
  • Flowabi lity is a bulk powder characteristic.
  • the term “flowable” means an irreversible deformation of a powder to make it flow due to the application of external energy or force.
  • "Aerosolized” or “aerosolizable” particles are particles which, when dispensed into a gas stream by either a passive or an active inhalation device, remain suspended in the gas for an amount of time sufficient for at least a portion of the particles to be inhaled by the patient, so that a portion of the particles reaches the lungs.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic, acid or base addition salts of compounds of disclosed herein. Representative salts include, for example, those listed in Berge el ah, “Pharmaceutical Salts,” J. Pfiarm Sci, Vol. 66, pp. 1-19, (1977).
  • Pharmaceutically acceptable acid addition salts include, but are not limited to, those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p- toluenesulphonic, benzenesulphonic, isethionic, and naphthalenecarboxylic, such as l-hydroxy-2-naphthalenecarboxylic (i.e., xinafoic) acids.
  • Aerodynamic diameter denotes the diameter of a sphere of unit density which behaves aerodynamically as the particle of the test substance. It is used to compare particles of different sizes, shapes and densities and to predict where in the respiratory tract such particles may be deposited. The term is used in contrast to volume equivalent, optical, measured or geometric diameters which are representations of actual diameters which in themselves cannot be related to deposition within the respiratory tract.
  • the aerodynamic diameter, daer can be calculated from the equation: where d g is the geometric diameter, for example the Mass Median Aerodynamic Diameter" (MMAD), and p is the powder density. See, for example, U.S. Patent No. 9,539,211, the disclosure of which is incorporated herein by reference in its entirety.
  • MMAD Mass Median Aerodynamic Diameter
  • Total flow energy represents a powder' s resistance to being made to flow in a dynamic state. It can be calculated from measurements of rotational resistance (Torque) and vertical resistance (Force) experienced by a blade moving through a column of powder in a rheometer.
  • blend uniformity refers in general to a measure of the uniformity of a blend of powder.
  • the FDA published a draft guidance document for analyzing blend uniformity in August 1999 FDA, "Guidance for Industry; AND As: Blend Uniformity Analysis," August 3, 1999, available at h
  • the draft guidance document states that an "acceptable blend uniformity,” which is defined herein with die same definition, is one in which 90.0 to 1 10.0 percent of the expected quantity of the active ingredient is recovered with a relative standard deviation (RSD) of no more than 5.0%.
  • RSD relative standard deviation
  • An aspect of the disclosure provides a method for the manufacture of drug inhalation powders, particularly powders for use in a dry powder inhaler (DPI). More specifically, embodiments include methods for characterizing the cohesiveness of powders comprising a drug or active agent to facilitate the manufacture of homogeneous dry powder blends. The methods are particularly useful for screening batches of micronized APIs to select batches that can be mixed under standardized conditions and still achieve blend uniformity. [034] In one embodiment, powder rheology is used for the measurement of inter-particulate forces in bulk powders and provides a measurement of the cohesiveness of individual batches of an active pharmaceutical ingredient (API).
  • API active pharmaceutical ingredient
  • the total flow energy can be measured on an FT4 Powder Rheometer® (commercially available from Freeman Technology, Gloucestershire, United Kingdom), which measures the energy required by a screw/blade to travel a fixed distance in a powder bed.
  • Cohesive materials which have strong inter-particulate forces, provide more resistance to the travel of the screw/blade and have higher total flow energy. It has been discovered that total flow energy correlates very well with the tapped density of the material, since a powder which is well packed requires more energy to overcome inter- particulate forces and move the particles, which in turn may correlate with the cohesiveness between API particles which can have influence in achieving good blend uniformity of powder formulation, thereby providing a fast and effective method of determining powder suitability. This method allows for selection of suitable batches of API to be used in the manufacture of homogeneous powder blends.
  • the embodiments may optionally include first conditioning a powder.
  • Powders have memory, in that their behavior and flowability can be influenced by their previous packing state. Powders are complex materials that primarily contain three distinct phases: (1) solids in the form of particles; (2) gases in the form of air between the particles; and (3) often liquids in the form of water either on the surface of the particles or within its structure.
  • the behavior of powders such as flowability, compressibility, adhesivity, permeability, hydrophobicity, etc., is difficult to model and predict from first principles. Powder behavior is a function not only of the physical and chemical properties of the particles, but external variables such as packing, moisture levels, electrostatic charge, etc.
  • the conditioning process involves gentle displacement of the whole sample in order to loosen and slightly aerate the powder.
  • the aim is to disturb and gently drop each particle in order to construct a homogenously packed powder bed, removing any pre-compaction or excess air and ensuring the results from the following test are independent of how the operator handles the powder and places it into the testing vessel.
  • a bulk API powder can be conditioned by downward traverse of a rheometer blade and then upward traverse to establish a low stress, homogeneous packing state, free of localized stress and any excess air, as shown in Figure 2.
  • the downward traverse uses a 5° positive helix where the blade action is more slicing than compacting; the upward traverse uses a 5° negative helix that gently lifts the powder and drops it over the blade with each particle coming to rest behind the blade.
  • a particularly preferred apparatus used to condition powders is the FT4 Powder Rheometer®, commercially available from Freeman Technology, Gloucestershire, United Kingdom.
  • the embodiments described herein may include determining the tapped density of a powder, which is the ratio of the mass of the powder to the volume occupied by the powder after it has been tapped for a defined period of time.
  • the tapped density of a powder may be measured by first gently introducing a known mass of a sample powder into a vessel (e.g., a graduated cylinder) and carefully leveling die powder without compacting it. The cylinder is then mechanically tapped by raising the cylinder and allowing it to drop under its own weight using a mechanical tapped density tester that provides a suitable fixed drop distance and nominal drop weight. Volume or weight readings are taken until little further volume or weight change is observed.
  • the tapped density of a powder may be measured by first gently introducing an excess known mass of a sample powder into a vessel with a known volume (e.g., FT4 split vessel assembly or cylinder or equivalent) and conditioning the powder.
  • the cylinder is then mechanically tapped by raising the cylinder and allowing it to drop under its own weight using a mechanical tapped density tester that provides a suitable fixed drop distance and drop weight. After tapping remove excess weight from the cylinder with known volume. Weight readings are taken until little further weight change is observed.
  • Tapped density is distinguished from bulk density, which is the mass per unit volume of a loose (untapped) powder bed. Methods for the determination of bulk density and tap density are provided in the United States Pharmacopeia Convention, 2014, Chapter 616, "Bulk Density and Tapped Density of Powders.” Any apparatus can be used to measure the tapped density, including the use of a single platform tapped density tester (Varian Inc., North Carolina, USA), or a split vessel assembly used in an FT4 Powder Rheometer® (Freeman Technology,
  • the tapping frequency and number of taps can be different as long as the combination of both parameters results in constant tapped density as per compendial requirements.
  • the tapping drop height is between 3 ⁇ 2 mm to 20 ⁇ 2 mm
  • the tapping frequency is about 200 to about 400 taps per minute with about 250 to about 2S00 total taps.
  • the tapping frequency is about 225 to about 350 taps per minute with about 250 to about 2500 total taps.
  • the tapping frequency is about 250 to about 300 taps per minute, with about 500 to about 2500 total taps.
  • the tapping frequency is about 300 taps per minute for a total of about 400 taps.
  • the fixed drop distance used to determine tapped density can also be varied according to the API.
  • the tap density tester is set to a drop height of from about 3 ⁇ 2 mm to about 20 ⁇ 2 mm, preferably from about 6 ⁇ 2 mm to about 20 ⁇ 2 mm, and more preferably from about 9 ⁇ 2 mm to about 20 ⁇ 2 mm.
  • the tap density tester is set to a drop height of from about 10 ⁇ 2 mm to about 20 ⁇ 2 mm.
  • the tap density tester is set to a drop height of from about 10 ⁇ 2 mm to about 14 ⁇ 2 mm.
  • the embodiments described herein may also include determining the total flow energy of a powder, which can be done for example, using an FT4 Powder Rheometer® (Freeman
  • the FT4 Powder Rheometer was designed to characterize the rheology, or flow properties, of powders. To measure total flow energy, a blade can be rotated and moved downward through a powder to establish a precise flow pattern. The more difficult it is to move the blade, the more the particles resist motion and the harder it is to get the powder to flow. As the blade rotates and moves vertically, it will experience a resistance to rotation and a resistance to vertical movement.
  • the FT4 Powder Rheometer measures both rotational and vertical resistance in the form of Torque and Force, respectively. The composite of these two signals quantifies the powder's total resistance to flow. Using the calculation of Work Done it is possible to represent both resistances as a total energy, the energy required to move the blade from the top to the bottom of the powder column.
  • the rheometer blades are configured to move downward through the powder in a helical path defined by the helix angle and blade tip speed.
  • the parameters for helix angle and tip speed can be modified and optimized, depending on the material used, and those skilled in the art will be capable of optimizing these parameters using the guidelines provided herein.
  • the blades traverse downward through the powder in a counter-clockwise helical path at a helix angle of from about 3° to about 7°.
  • the blade tip speed is from about SO to about 300 mm/sec, preferably from about 100 to about 300 mm/sec, and more preferably from about 200 to about 300 mm/sec.
  • the blades traverse downward through the powder at a helix angle of 5° positive at a tip speed of about 100 mm/sec.
  • the embodiments further may include determining whether a correlation exists between the tapped density and total flow energy of the powder, preferably a linear correlation.
  • Determining whether a correlation exists between tapped density and total flow energy can be determined by plotting the respective product characteristics and assessing whether a correlation between the characteristics exists (see, e.g., Figure 4). If no or little correlation exists, then it can be assumed that tapped density of the powder would not be an appropriate indicator for the final product characteristics. If it is determined that a correlation exists, then the embodiments may include further determining the API cohesiveness and blend uniformity of the powder.
  • the blend uniformity of the powder can be determined using any known method, including for example, those disclosed in the draft guidance document.
  • the blend uniformity for the powder then can be correlated with the tapped density and/or the total flow energy. If a correlation exists between acceptable blend uniformity and tapped density, the embodiments include establishing a threshold tapped density to achieve acceptable blend uniformity - i.e., one in which 90.0 to 110.0 percent of the expected quantity of the active ingredient is recovered with a relative standard deviation (RSD) of no more than 5.0%.
  • RSD relative standard deviation
  • the threshold tapped density then can be used as a simple test to assess the material quality to achieve adequate blend uniformity.
  • the embodiments include establishing a threshold total flow energy to achieve an acceptable blend uniformity.
  • various powders can be analyzed to determine whether correlations exist between tapped density, total flow energy, and blend uniformity. If a correlation exists, then product manufacturers can simply use the determined threshold tapped density and/or threshold total flow energy as an API and/or product quality control determinant.
  • the method can be used with any powder pharmaceutical agent.
  • the powder active pharmaceutical ingredient (API) can be a bronchodilator.
  • the bronchodilator can be a Short-Acting Beta Adrenoceptor Agonist (SABA), such as albuterol, bitolterol, fenoterol, isoproterenol, levalbuterol, metaproterenol, pirbuterol or procaterol, a Long Acting Beta
  • SABA Short-Acting Beta Adrenoceptor Agonist
  • Adrenoceptor Agonist such as arformoterol, bambuterol, clenbuterol, formoterol or salmeterol, or an Ultra Long Acting Beta Adrenoceptor Agonist (Ultra-LABA), such as abediterol, carmoterol, indacaterol, olodaterol or vilanterol.
  • LAA Adrenoceptor Agonist
  • Ultra-LABA Ultra Long Acting Beta Adrenoceptor Agonist
  • the API may be an anticholinergic agent that blocks the activity of the muscarinic acetylcholine receptor, including a Short-Acting Muscarinic Antagonist (SAMA) such as ipratropium, or a Long-Acting Muscarinic Agent (LAMA), such as aclidinium, glycopyrronium, tiotropium, and umeclidinium.
  • SAMA Short-Acting Muscarinic Antagonist
  • LAMA Long-Acting Muscarinic Agent
  • the API may be an inhaled corticosteroid (ICS) such as, for example, budesonide, ciclesonide, flunisolide, beclomethasone, fluticasone, mometasone or triamcinolone.
  • the API is a pharmaceutically acceptable salt of any of the above- mentioned APIs.
  • the API is another powder API known in the art or later discovered, or mixtures of one or more of any of the above-mentioned APIs.
  • the powder formulations can be utilized with any type of DPIs known in the art.
  • DPIs can be divided into two basic types: (i) single dose inhalers, for the administration of pre- subdivided single doses of the active compound; and (ii) multidose dry powder inhalers (MDPIs), either with pre-subdivided single doses or pre-loaded with quantities of active ingredient sufficient for multiple doses.
  • MDPIs multidose dry powder inhalers
  • DPIs can be further classified on the basis of the required inspiratory flow rates (L/min), which in turn depend on their design and mechanical features.
  • DPIs can be classified as: (i) low-resistance devices (> 90 IJmin); (ii) medium-resistance devices (about 60 L/min); and (iii) high-resistance devices (about 30 L/min).
  • the equipment used to measure the tapped density and total flow energy of the Active Pharmaceutical Ingredient (API) was a 25 mm x 25 mL Split Vessel Assembly shown in FIG. 1. This assembly may be included as part of an FT4 Powder Rheometer® (commercially available from Freeman Technology, Gloucestershire, United Kingdom). The assembly was constructed using the following procedure.
  • the levelling assembly was tightened with a hex driver or other suitable tooling; (7) The vessel was held to ensure that the vessel and split mechanism were flush by running your finger around the top; (8) The levelling assembly was closed, the 25 mm x 25 mL extension vessel was placed into the top half of the levelling assembly gently rotated to ensure it was in contact with the vessel below, and then gently tightened with a hex driver or other suitable tooling; and (9) The funnel was placed on top.
  • the Split Vessel Assembly is shown in Figure 1.
  • a powder sample of API was conditioned to loosen and remove any pre-compaction, slightly aerate the powder and construct a homogenously packed powder bed.
  • the conditioned powder was consolidated by tapping, and its tap density measured.
  • the flowability of the consolidated powder was measured using an FT4 Powder Rheometer® (Freeman Technology, Ltd., Gloucestershire, UK). The testing procedure was repeated with additional samples of the same powder and then the data used to correlate the tap density (g/mL) and total flow energy (mJ) for the powder.
  • a powder sample of API was prepared for both tapped density and total flow energy measurements according to the following procedure: (i) The 25mm X 25 mL split vessel assembly with a feeding funnel discussed above was attached to an FT4 Powder Rheometer instrument table, supplied by Freeman Technology); (ii) The empty vessel was tared to the nearest 0.01 g; (iii) Approximately 8 ⁇ 0.50 g of micronized Active Pharmaceutical Ingredient (API) was charged into the vessel assembly via the feeding funnel and allowing powder excess using a stainless steel spatula; (iv) The bulk API was conditioned by downward traverse of the FT4 Rheometer blade and then upward traverse to establish a low stress, homogeneous packing state, free of localized stress and any excess air.
  • API micronized Active Pharmaceutical Ingredient
  • the downward traverse used a 5° positive helix where the blade action is more slicing than compacting; the upward traverse used a 5° negative helix that gently lifts the powder and drops it over the blade with each particle coming to rest behind the blade.
  • the downward traverse and upward traverse of the FT4 Rheometer blade in the conditioning step is shown in Figure 2.
  • the tapped density of powder sample was measured with a standard tap density tester (e.g., VanKel® Tap Density Tester, Varian Inc., Cary, North Carolina) according to the following procedure: (i) The split vessel assembly containing the conditioned API was transferred to the holder on top of the tapped density tester and the vessel secured; (ii) The Tapped Density Tester was set at S taps per second for a total of 400 taps with a drop height at 14 ⁇ 2 mm, and Tester was started to begin mechanical tapping; (iii) Excess powder was split from the split vessel assembly and the final powder weight was measured after tapping.
  • a standard tap density tester e.g., VanKel® Tap Density Tester, Varian Inc., Cary, North Carolina
  • the FT4 instrument can calculate the tapped density based on the calculated / weighted mass of the tapped powder and fixed volume of the split vessel assembly.
  • Step 3 After measuring the flowability of the powder as described in Step 3, additional samples (i.e., units of the powder) were tested in order to calculate average values for tapped density and total flow energy.
  • the procedure was as follows: (i) The standard base was gently pulled out of the Split Vessel Assembly to transfer all the powder from the sample tested into a stainless steel waste container with the aid of stainless steel spatula and the cleaning brush; (ii) The standard base was placed back over the Split Vessel Assembly; (iii) Steps 1-3 were repeated once or twice with fresh sample of the same powder in order to determine the tapped density and total flow energy of additional powder samples; (iv) The average tapped density (g/mL) and average total flow energy (mJ) was calculated for the powder based on collected data for a plurality of units of the powder.
  • Example 3 Correlating Average Tapped Density and Average Total Flow Energy
  • Consolidating the bulk powder i.e., tapping to produce the tapped density
  • tapping appears to facilitate the cohesiveness between the API particles and allows for more discrimination between different batches of API with different bulk densities.
  • the enhanced discrimination via tapping it also allows the total flow energy technique to be more discriminatory because higher energy is required to move the consolidated powder. Therefore, good correlation between tapped density and total flow energy in the consolidated powder is observed.
  • Blend uniformity was determined according to the FDA, "Gui dance for Industry; Powder Blends and Finished Dosage Units - Stratified In-Process Dosage Unit Sampling and
  • blend uniformity was assessed by collecting and assaying 10 samples from 10 sampling locations in the blender and/or intermediate bulk containers. The mean and relative standard deviations (RSD) of all individual results were then calculated. To meet Tier 1 criteria, the RSD of all individual results is ⁇ 5.0% and all individual results are within 10.0% (absolute) of the mean of the results. In the event of not meeting Tier 1 acceptance criteria, an additional 2 samples from each of the 10 locations were sampled and assayed according to Tier 2 criteria.
  • salmeterol xinafoate batches with high average tapped density such as 0.31 g/mL for SXI1112025 (Batch 7), 0.32 g/mL for SXI0113001 (Batch 8) and 0.30 g/mL for SXI0516024 (Batch 17), have a high tendency to result in blend uniformity failure.
  • salmeterol xinafoate raw material batches with lower average tapped density values are generally suitable for manufacturing fluticasone propionate / salmeterol xinafoate inhalation powder blends.
  • salmeterol xinafoate batches with high total flow energy have a greater tendency to result in blend uniformity failure and batches with low total flow energy are generally suitable for binary blends with fluticasone propionate.
  • the total flow energy and tapped density as determined by the inventive method is useful for distinguishing the quality of salmeterol xinafoate raw material that is suitable for manufacturing inhalation powder blends.
  • the inventive methods have demonstrated utility for the manufacture of binary blends of salmeterol xinafoate with fluticasone propionate, a combination useful for the management of asthma and chronic obstructive pulmonary disease.
  • the inventive method can be applied to other powder blends containing Sx. The method may need to be repeated because, for some powders, it cannot be assumed that a threshold tapped density or threshold total flow energy for one API suitable for a particular powder blend extends to other blends with the same API.
  • APIs other than salmeterol xinafoate used in inhalation powder blends.
  • Suitable APIs include, but are not limited to, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), short acting muscarinic antagonists (SAMA), and long acting muscarinic antagonists (LAMA).

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés de caractérisation de poudres et/ou d'évaluation de la pertinence de poudres pour la fabrication d'un mélange de poudres. Les procédés consistent à caractériser la cohésivité d'une poudre comprenant un médicament ou un principe actif afin de déterminer la pertinence de celle-ci pour la fabrication de mélanges de poudres à inhaler.
PCT/US2018/052329 2017-09-22 2018-09-22 Procédé de fabrication de poudres à inhaler WO2019060797A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561974P 2017-09-22 2017-09-22
US62/561,974 2017-09-22

Publications (2)

Publication Number Publication Date
WO2019060797A1 true WO2019060797A1 (fr) 2019-03-28
WO2019060797A9 WO2019060797A9 (fr) 2019-06-13

Family

ID=63841038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052329 WO2019060797A1 (fr) 2017-09-22 2018-09-22 Procédé de fabrication de poudres à inhaler

Country Status (1)

Country Link
WO (1) WO2019060797A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078695A2 (fr) 2000-04-17 2001-10-25 Vectura Limited Formulations pharmaceutiques pour inhalateur a poudre seche
US20140326812A1 (en) * 2009-04-24 2014-11-06 Iceutica Pty Ltd. Method for the Production of Commercial Nanoparticle and Microparticle Powders
US9539211B2 (en) 2012-11-09 2017-01-10 Civitas Therapeutics, Inc. Ultra low density pulmonary powders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078695A2 (fr) 2000-04-17 2001-10-25 Vectura Limited Formulations pharmaceutiques pour inhalateur a poudre seche
US20140326812A1 (en) * 2009-04-24 2014-11-06 Iceutica Pty Ltd. Method for the Production of Commercial Nanoparticle and Microparticle Powders
US9539211B2 (en) 2012-11-09 2017-01-10 Civitas Therapeutics, Inc. Ultra low density pulmonary powders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERGE: "Pharmaceutical Salts", J. PHARM SCI, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104
IBRAHIM ET AL., MEDICAL DEVICES: EVIDENCE AND RESEARCH, vol. 8, 2015, pages 131 - 139
LETURIA M ET AL: "Characterization of flow properties of cohesive powders: A comparative study of traditional and new testing methods", POWDER TECHNOLOGY, vol. 253, 12 December 2013 (2013-12-12), pages 406 - 423, XP028610104, ISSN: 0032-5910, DOI: 10.1016/J.POWTEC.2013.11.045 *
WEISS ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 494, 2015, pages 393 - 407

Also Published As

Publication number Publication date
WO2019060797A9 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
US20230364015A1 (en) Process for providing particles with reduced electrostatic charges
Kaialy et al. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate
CN105338960B (zh) 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂
CN104080444B (zh) 用于吸入给药包含皮质类固醇和beta‑肾上腺素能药物的干粉配制剂
JP5818801B2 (ja) 改善された製剤
CN108348614A (zh) 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
CN108289962A (zh) 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
CN109200034A (zh) 一种可吸入干粉形式的组合物及其制备方法
WO2019067708A1 (fr) Procédé pour diminuer la taille de particules
CN105658334B (zh) 制备包含高剂量强度活性成分的吸入用药物制剂的方法
WO2019060797A1 (fr) Procédé de fabrication de poudres à inhaler
US20070178157A1 (en) Process for cleaning hard gelatine capsules
WO2016005440A1 (fr) Procédé de préparation de formulations de poudre sèche
Cordts Advanced Powder Characterization Techniques for Inhalation Powder Mixtures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18786133

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18786133

Country of ref document: EP

Kind code of ref document: A1